Melanoma Mutation Profiling For Personalised Treatment
Funder
National Health and Medical Research Council
Funding Amount
$571,191.00
Summary
Melanoma is an aggressive skin cancer, and the leading cause of skin cancer related deaths. Disease spread is difficult to detect and extremely difficult to cure. This bleak clinical outcome is changing with the development of personalised therapies which include small molecule inhibitors to treat metastatic melanoma. Here we seek to identify the spectrum of mutations in patient tumours and circulating tumour cells for advanced personalised treatment.
The Role Of Melanoma Tumour Antigen P97 (Melanotransferrin) In Melanoma Tumourigenesis.
Funder
National Health and Medical Research Council
Funding Amount
$563,242.00
Summary
The Role of Melanoma Tumour Antigen p97 (Melanotransferrin) in Melanoma Tumourigenesis Melanotransferrin (MTf) is a homologue of the iron transport protein, transferrin, and was one of the first well characterised melanoma tumour antigens. Our published studies have shown that MTf plays an important role in melanoma tumourigenesis in vivo. In this proposal, we will assess if it is associated with melanoma progression in patient samples and examine its role in melanoma growth and metastasis.
Early diagnosis of melanoma remains extremely challenging. Currently there are no validated blood-based biomarkers for early diagnosis. Therefore, a reliable screening test is an unmet medical need. Autoantibodies are emerging as promising biomarkers for early cancer detection. In a proof of principle experiment we identified five autoantibodies that provide 95% sensitivity / specificity. Now we will confirm and validate our findings and develop a clinical test for melanoma diagnosis.
Liquid Biopsy For Personalised Monitoring Of Melanoma Patients
Funder
National Health and Medical Research Council
Funding Amount
$820,888.00
Summary
Despite the success of recent melanoma treatments, therapies are effective long term in only a proportion of patients. Here we will progress preliminary findings in collaboration with biotechnology and pathology companies to develop highly effective companion biomarkers that will aid treatment decisions throughout disease course. Our team will spearhead translation of these markers into the clinic for routine monitoring of melanoma patients.
Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
KConFab - The Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$2,176,975.00
Summary
Breast cancer is the most common malignant disease of women. In families with an inherited form of breast cancer, nearly half the women in every generation can develop the disease. The aim of this Australasian-wide study is to complete collection of clinical, epidemiological and genetic data on 1,600 of these severely-affected families. The national resource is, and will continue to be, of great value for researchers who want to identify and characterize the genetic and life style factors that a ....Breast cancer is the most common malignant disease of women. In families with an inherited form of breast cancer, nearly half the women in every generation can develop the disease. The aim of this Australasian-wide study is to complete collection of clinical, epidemiological and genetic data on 1,600 of these severely-affected families. The national resource is, and will continue to be, of great value for researchers who want to identify and characterize the genetic and life style factors that affect onset and progression of the disease.Read moreRead less
Can Exercise Delay Transition To Active Therapy In Men With Low Grade Prostate Cancer? A Multi-Centre Randomized Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$604,429.00
Summary
Prostate cancer overdiagnosis is associated with increased rates of overtreatment and associated morbidity. Although nearly half of Australian men diagnosed with low risk prostate cancer are managed with active surveillance there are no established recommendations for slowing disease progression and delaying transition to active treatment. The proposed study would be the first to determine the efficacy of a comprehensive exercise program during active surveillance for prostate cancer.
Leukaemia-cancer cells have altered biochemical properties resulting in their high rate of growth compared to normal cells. One of these is augmented activity of enzymes called tyrosine kinases including members of the Src family. One called Lyn has been implicated in several leukaemias as well as cancer. We have identified a novel mechanism of down-regulating this family of enzymes mediated by small proteins. These may allow us to develop novel therapeutics for cancer-leukaemia treatment.
Developing Interpretable Machine Learning Models For Clinical Imaging And Single-cell Genomics
Funder
National Health and Medical Research Council
Funding Amount
$1,312,250.00
Summary
Machine learning methods will be vital to make best use of the deluge of data generated by high-throughput technologies in biomedical science. To get the most out of these models, however, we need to be able to unpack the 'black box'. I will use curated clinical and public research data to benchmark and develop interpretable deep learning models and software tools. These models will be used for breast cancer screening programs and for analysis of complex, large-scale single-cell genomics data.
A Phase III Trial Comparing Adjuvant Versus Salvage Radiotherapy For High Risk Patients Post Radical Prostatectomy
Funder
National Health and Medical Research Council
Funding Amount
$819,138.00
Summary
About half of all patients Treated with an operation to remove their prostate cancer have a high chance of the cancer coming back. Giving immediate radiotherapy to all patients will improve cure rates but does not benefit all men and can cause significant side effects. This study explores whether it is safe to wait and only give radiotherapy when there is a rising PSA after surgery indicating active cancer. A total of 470 men from Australasia will enter this study comparing the two approaches.